Safe and effective sedation in endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma: a randomized comparsion between propofol and midazolam.

Safe and effective sedation in endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma: a randomized comparsion between propofol and midazolam. - Propofol vs midazolam for sedation in endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013601

Enrollment

132

Registered

2014-04-03

Start date

2014-04-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

superficial esophageal squamous cell carcinoma

Interventions

propofol sedation midazolam sedation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with superficial esophageal squamous cell carcinoma planned ESD. Above 20 years old. Adequate organ function. No allergic episode with propofol and midazolam. Written IC obtained from patients.

Exclusion criteria

Exclusion criteria: Severe disease in heart, lung, liver, or kidney. Allergic episode with propofol or midazolam. Women in pregnancy or breast-feeding Any other reasosn by which docter judged inappropriate case.

Design outcomes

Primary

Measure	Time frame
therapeutic interruption rate	—

Secondary

Measure	Time frame
therapeutic achievement rate treatment time adverse event risk factors for a poor response to sedation recovery time satisfaction	—

Countries

Japan

Contacts

Public ContactMasaki Ominami

Osaka City University Graduate School of Medicine Department of Gastroenterology

komesoudoh@yahoo.co.jp06-6645-3811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026